Literature DB >> 1589404

Estimation of permanence time, exit time, dilution factor, and steady-state volume of distribution.

J Mordenti1, A Rescigno.   

Abstract

General solutions for exist time, permanence time, dilution factor, and volume of distribution at steady state are derived for compartmental and noncompartmental systems. These derivations require that the systems are linear and state-determined. Unique values for these parameters cannot be determined when the site of elimination is not known; in this case the parameters can be defined by a range. Interpretation of this range and its significance and use in clinical situations are illustrated with two examples.

Mesh：

Year:  1992        PMID： 1589404     DOI： 10.1023/a:1018915307554

Source DB:  PubMed          Journal:  Pharm Res        ISSN： 0724-8741            Impact factor:   4.200


  16 in total

Review 1.  Noncompartmental versus compartmental modelling in clinical pharmacokinetics.

Authors:  W R Gillespie
Journal:  Clin Pharmacokinet       Date:  1991-04       Impact factor: 6.447

Review 2.  Mean time parameters in pharmacokinetics. Definition, computation and clinical implications (Part I).

Authors:  P Veng-Pedersen
Journal:  Clin Pharmacokinet       Date:  1989-11       Impact factor: 6.447

3.  Mean interconversion times and distribution rate parameters for drugs undergoing reversible metabolism.

Authors:  H Y Cheng; W J Jusko
Journal:  Pharm Res       Date:  1990-10       Impact factor: 4.200

4.  Model-free evaluation and mean-time concept in pharmacokinetics.

Authors:  D Brockmeier
Journal:  Methods Find Exp Clin Pharmacol       Date:  1986-10

5.  Some clarifications regarding moments of residence times with pharmacokinetic models.

Authors:  S L Beal
Journal:  J Pharmacokinet Biopharm       Date:  1987-02

6.  Interpretation and estimates of mean residence time with statistical moment theory.

Authors:  Y Kasuya; H Hirayama; N Kubota; K S Pang
Journal:  Biopharm Drug Dispos       Date:  1987 May-Jun       Impact factor: 1.627

7.  General treatment of mean residence time, clearance, and volume parameters in linear mammillary models with elimination from any compartment.

Authors:  E Nakashima; L Z Benet
Journal:  J Pharmacokinet Biopharm       Date:  1988-10

8.  Some considerations on the estimation of steady state apparent volume of distribution and the relationships between volume terms.

Authors:  P S Collier
Journal:  J Pharmacokinet Biopharm       Date:  1983-02

9.  Statistical moments in pharmacokinetics.

Authors:  K Yamaoka; T Nakagawa; T Uno
Journal:  J Pharmacokinet Biopharm       Date:  1978-12

10.  Biological properties of a CD4 immunoadhesin.

Authors:  R A Byrn; J Mordenti; C Lucas; D Smith; S A Marsters; J S Johnson; P Cossum; S M Chamow; F M Wurm; T Gregory; J E Groopman; D J Capon
Journal:  Nature       Date:  1990-04-12       Impact factor: 49.962
View more
  7 in total

Review 1.  Compartmental analysis and its manifold applications to pharmacokinetics.

Authors:  Aldo Rescigno
Journal:  AAPS J       Date:  2009-11-25       Impact factor: 4.009

2.  Potential errors in the volume of distribution estimation of therapeutic proteins composed of differently cleared components.

Authors:  Wolfgang F Richter; Hans Peter Grimm; Frank-Peter Theil
Journal:  J Pharmacokinet Pharmacodyn       Date:  2011-07-21       Impact factor: 2.745

3.  Hematopoietic cells as site of first-pass catabolism after subcutaneous dosing and contributors to systemic clearance of a monoclonal antibody in mice.

Authors:  Wolfgang F Richter; Gregory J Christianson; Nicolas Frances; Hans Peter Grimm; Gabriele Proetzel; Derry C Roopenian
Journal:  MAbs       Date:  2018-05-09       Impact factor: 5.857

4.  The pharmacokinetics and absorption of recombinant human relaxin in nonpregnant rabbits and rhesus monkeys after intravenous and intravaginal administration.

Authors:  S A Chen; B Reed; T Nguyen; N Gaylord; G B Fuller; J Mordenti
Journal:  Pharm Res       Date:  1993-02       Impact factor: 4.200

5.  Pharmacokinetics and tissue distribution of recombinant human transforming growth factor beta 1 after topical and intravenous administration in male rats.

Authors:  T F Zioncheck; S A Chen; L Richardson; M Mora-Worms; C Lucas; D Lewis; J D Green; J Mordenti
Journal:  Pharm Res       Date:  1994-02       Impact factor: 4.200

6.  The pharmacokinetics of recombinant human relaxin in nonpregnant women after intravenous, intravaginal, and intracervical administration.

Authors:  S A Chen; A J Perlman; N Spanski; C M Peterson; S W Sanders; R Jaffe; M Martin; T Yalcinkaya; R C Cefalo; N C Chescheir
Journal:  Pharm Res       Date:  1993-06       Impact factor: 4.200

7.  Population pharmacokinetics of serelaxin in patients with acute or chronic heart failure, hepatic or renal impairment, or portal hypertension and in healthy subjects.

Authors:  Antoine Soubret; Yinuo Pang; Jing Yu; Marion Dahlke
Journal:  Br J Clin Pharmacol       Date:  2018-08-23       Impact factor: 4.335
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.